Research Article

Immunological and Endocrine Profile of Two Patients with Severe Subarachnoid Neurocysticercosis, Resistant to the Cysticidal Treatment

Laura Adalid-Peralta1*, Gladis Fragoso1, Edda Sciutto2, Marisela Hernández3, Agnès Fleury2–3, Helgi Jung1 and Graciela Cárdenas1*

1National Institute of Neurology and Neurosurgery, Mexico
2Peripheral Unit of the Institute for Biomedical Research at the National Institute of Neurology and Neurosurgery, México
3Institute of Biomedical Research, National Autonomous University of Mexico; Mexico
*Corresponding author: Graciela Cárdenas, National Institute of Neurology and Neurosurgery, D.F., 14269, Mexico City, Mexico, Tel: (+52 55) 5606 3822; Email: grace_goker@yahoo.de

Received: February 21, 2014; Accepted: July 21, 2014; Published: Aug 04, 2014

Abstract

Neurocysticercosis (NC) is a disease caused by the establishment of Taenia solium larvae in the central nervous system. NC may exhibit different clinical pictures depending on the location of the established cysticerci, their degenerating stage, and the intensity of the immune-inflammatory profile induced by the infection. Moreover, the response to cysticidal treatment is also heterogeneous. When cysticerci establish in the subarachnoid space of the base (SABNC) they are more frequently resistant to the treatment.

To further deepen our understanding of this resistant status, the central and peripheral inflammatory and endocrine profiles of two SABNC patients who failed to respond to four treatment cycles (albendazole plus corticosteroids) are herein reported.

Several immunological and endocrinological treatments were found altered: decreased levels of testosterone, cortisol, and prolactin were observed, accompanied by increased levels of immunomodulatory cytokines (TGF-β and IL-10), as well as LH.

Altogether, these results establish the impact of SABNC on the immune-inflammatory and endocrine status of both patients. The possible relevance of these changes in the NC pathogenesis is discussed.

Key words: Taenia solium; Neurocysticercosis; Treatment resistance; Taeniasolium

Background

Human cysticercosis is a parasitic infection caused by the establishment of Taenia solium larvae (cysticerci) in human tissues. In most cases, the parasite establishes in muscles and in the brain. The latter location leads to neurocysticercosis (NC), the most severe form of the disease [1]. The clinical presentation of NC varies from asymptomatic to mild to a severe neurological disease with intracranial hypertension. This heterogeneity mainly depends on the parasite location in the central nervous system [2]. NC patients lodging cysticerci in the parenchyma generally show an inflammatory response restricted to the area surrounding the cysts, exhibit a non-inflammatory cerebrospinal fluid (CSF) [2], and an effective response to the cysticidal treatment is usually observed [3]. In contrast, when cysticerci are located in the ventricles or in the subarachnoid space of the base (SABNC), most cases are accompanied by an increased CSF cellularity and may result in secondary intracranial hypertension.

Several findings support the hypothesis that the parasite gained, thorough millions of years of co-evolution with the host, the ability to manipulate its environment, promoting a comfortable milieu that favor its survival [4,5]. This is seems to be a common strategy developed by some large parasites that may persist for years in the host tissues without apparent inflammatory response [6].

The endocrine system could also participate in this immunomodulation, as it has been reported in other host-parasite interactions, both under experimental and natural conditions [7]. Regarding human NC few information and the role of immunoendocrine system is available [8].

In this report, we present the inflammatory and endocrine profiles of two SABNC patients harboring multiple parasites and who did not respond to several cycles of conventional cysticidal treatment (non-responder patients).

Case Presentations

Case 1

A 29 year-old Mexican man living in the United States of America suffered from sudden generalized seizures. CT scan showed NC. The patient was administered ABZ plus steroids. Afterward, progressive motor dysphasia, right sided weakness, and intracranial hypertension signs appeared and the patient came back to Mexico. MRI showed extensive racemose cysticerci on left Sylvian fissure with

Abbreviations

NC: Neurocysticercosis; SABNC: Subarachnoid of the base Neurocysticercosis; CSF: Cerebrospinal Fluid; INNN: Instituto Nacional de Neurología y Neurocirugía; ABZ: Albendazole; ABZ-SO: Albendazole Sulfoxide; HPLC: High-performance Liquid Chromatography; CT: Computed tomography; MRI: Magnetic resonance imaging; DXM: Dexamethasone; PZQ: Praziquantel; MTX: Methotrexate; PDN: Prednisone

displacement of anatomical structures off the medial line. ABZ at 30 mg/kg, plus dexamethasone (DXM) at 0.3 mg/kg were administered during 8 days. Motor weakness improved in the following months, and a control MRI showed a 95%-reduction of the giant racemose cysticercus, along with asymmetric dilation of the left ventricle secondary to encephalomalacia (the side where parasites were previously lodged), and also multiple new parasitic lesions in the cerebral media artery cisterns. Clinical improvement continued until 4 months later, when the patient developed suddenly intense headache associated to visual blurring and diplopia. The patient was hospitalized to receive an additional ABZ cycle with close medical supervision. In the clinical and radiological follow-up at 7, 9, 11, and 19 months, basal parasites located in the perimesencephalic region persisted and a new parasite in the third ventricle appeared. A total of 6 ABZ and DXM cycles and two combined ABZ and praziquantel (PZQ) cycles were administered, with neither clinical nor radiological evidence of parasite elimination (Table 1). (Some data from this patient were partially reported in BMC Neurol 2010:10:16.) [9].

**Case 2**

A 60 year-old Mexican man with a history of chronic headache. Nine months before hospital admission, headache frequency increased and it was associated with lower limb motor dysfunction. Neurological examination upon admission revealed only papilledema. On MRI, subarachnoid NC in the posterior fossa was observed and the patient received the first course of ABZ at 30 mg/kg plus DXM 0.3 mg/kg by 8 days. Mild clinical improvement was observed, but four months later the previous neurological alterations worsened. Due to adverse effect of steroid administration, methotrexate (MTX) was added instead of steroids. No radiological changes in the parasite number or size were observed on MRI, and a second course of ABZ and DXM at the same doses was administered. In the next monthly follow-ups, MRI showed parasite persistence, and a combined course of two cysticidal drugs (ABZ at 30 mg/kg and PZQ at 50 mg/kg) associated to DXM at 0.3 mg/kg was administered by 8 days. CSF analysis showed an inflammatory profile, with abundant lymphocytes and eosinophils, in spite of prednisone (PDN) and MTX administration. No radiological disappearance of parasites was observed in a control MRI, and the patient remained symptomatic after 3 cycles of ABZ alone and one combined cycle of ABZ and PZQ (Table 2).

**Material and Methods**

Immune-endocrine profiling and CSF analysis were conducted during the clinical follow-up of patients. The clinical and radiological characteristics of both patients are summarized in Tables 1 & 2. Several analyses on CSF recovered by lumbar puncture were conducted during clinical follow-up; these data are summarized in Table 3. A control group of 5 neurological patients with epilepsy or idiopathic intracranial hypertension and without NC was included.

Table 1: Clinical and radiological follow-up of case1 during ABZ cycles.

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Initial</th>
<th>1st</th>
<th>2nd</th>
<th>3rd</th>
<th>4th</th>
<th>5th</th>
<th>6th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroimaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of parasites</td>
<td>One racemose</td>
<td>One racemose</td>
<td>9</td>
<td>&gt;15</td>
<td>4</td>
<td>&gt;15</td>
<td>4</td>
</tr>
<tr>
<td>Clinical symptoms</td>
<td>Severe chronic headache, mild hemiparesis</td>
<td>Severe chronic headache</td>
<td>Severe chronic headache</td>
<td>Severe chronic headache</td>
<td>Severe chronic headache</td>
<td>Severe headache, depression and hemiplegia</td>
<td></td>
</tr>
<tr>
<td>CSF-cytchemistry</td>
<td>ND</td>
<td>G:70</td>
<td>P:19</td>
<td>C: 6</td>
<td>ND</td>
<td>G:107</td>
<td>P:24</td>
</tr>
<tr>
<td>ABZ-5O (ng/mL)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>3364.3</td>
<td>ND</td>
</tr>
</tbody>
</table>

*Number of cysticidal cycle, ND nodata available, G: glucose mg/dL, P: proteins mg/dL, C: cells/mm³, Lym: lymphocytes, Neu: neutrophils, Eo: eosinophils. ‡ Optical density; negative control had an optical density value 0.021.
Ethical considerations

This study fulfills all research regulations for human beings required by Mexican laws and international regulations. Patients volunteered to enter the study, donated blood and CSF samples, and signed an informed consent form.

Biological specimens

Blood and CSF samples were aseptically taken from both patients during clinical follow-up and frozen at –80°C in sterile containers until used.

Investigations

Cytokine levels

CSF cytokine levels in NC patients were measured using a Th1/Th2 Cytokine Kit II (BD eBiosciences Pharmingen) and a cytometric bead array. The procedure was carried out according to the manufacturer’s directions. Fluorescence measurement and analysis were performed using a FACSCalibur flow cytometer and the BD Cytometric Bead Array software (BD Biosciences Pharmingen). Flow cytometer was calibrated by using BD FACSComp (BD Biosciences Pharmingen) and BD CaliBRITE Beads (BD Biosciences Pharmingen). Assay sensitivities were as follows: IL-6, 3.0 pg/mL; IL-10, 2.8 pg/mL; TNF-α, 2.8 pg/mL, and IFN-γ, 7.1 pg/mL. TGFβ (sensitivity: 9.4 pg/mL) was measured by using the human/mouse TGF-beta 1 ELISA Ready-SET-Go (Bioscience, San Diego, CA). ELISA was performed according to the manufacturer’s instructions. All samples were run in duplicate.

HP10 antigen detection

To evaluate the parasite viability after NC treatment, HP10 antigen was detected by Ag-ELISA as previously described [8]. All samples were run in duplicate. Briefly, Immulon I plates (Nunc, Rochester, New York, USA) were coated with monoclonal HP10 antibody (100 mL at 10 mg/mL in 0.07 M NaCl buffered with 0.1 M borate, pH 8.2) and left overnight at 4°C. Plates were washed four times with 200 mL/well of wash solution (0.9% w/v NaCl containing 0.05% v/v Tween 20). Plates were blocked using 200 mL diluents (phosphate-buffered saline containing bovine serum albumin 1.0% w/v and 0.05% v/v Tween 20) and left for 60 min at room temperature before being washed in a similar way. Undiluted CSF or serum samples (100 mL/well) were added and incubated for 30 min at 37°C. Bound HP10 parasite antigen was detected using biotinylated monoclonal antibody HP10 (1:4000 in diluents, for 30 min at 37°C), horseradish peroxidase-conjugated streptavidin (Zymed, San

Table 2: Clinical and radiological follow-up of case 2 during ABZ cycles.

<table>
<thead>
<tr>
<th>Case2</th>
<th>Initial</th>
<th>1st</th>
<th>2nd</th>
<th>3rd</th>
<th>4th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroimaging</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
</tr>
<tr>
<td>Number of parasites</td>
<td>5</td>
<td>9</td>
<td>12</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Clinical symptoms</td>
<td>Chronic headache, slight hemiparesis</td>
<td>Severe chronic headache and meningitis</td>
<td>Severe chronic headache and myopathy</td>
<td>Severe chronic headache and myopathy</td>
<td>Chronic headache, myopathy, and iatrogenic Cushing syndrome</td>
</tr>
<tr>
<td>CSF cytochemistry</td>
<td>G: 0 P: 176 C: 770 (Lym 98%, Neu 2%)</td>
<td>G: 1 P: 170 C: 3149 (Lym 8%, Neu 90%, Eo 2%)</td>
<td>G: 26 P: 32 C: 37 (Lym 21%, Neu 77%, Eo 2%)</td>
<td>G: 53 P: 31 C: 160 (Lym 66%, Neu 32%, Eo 2%)</td>
<td>G: 2 P: 92 C: 80 (Lym 93%, Neu 7%)</td>
</tr>
<tr>
<td>ABZ-SO (mg/mL)</td>
<td>ND</td>
<td>2421.8</td>
<td>2430</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>HP10</td>
<td>ND</td>
<td>1.103</td>
<td>1.117</td>
<td>0.80</td>
<td>0.77</td>
</tr>
</tbody>
</table>

*Number of cysticidal cycle, ND nodata available, G: glucose mg/dL, P: proteins mg/dL, C: cells/mm3, Lym: lymphocytes, Neu: neutrophils, Eo: eosinophils. ‡Optical density; negative control had an optical density value 0.021.
Graciela Cárdenas

Austin Publishing Group

Francisco, California, USA) (1:4000 in diluents, 30 min at 37°C) and tetramethylbenzidine (Zymed) as substrate. The color reaction was allowed to proceed for 30 min at 37°C in the dark and was stopped by adding 100ml H2SO4 (Baker, Estado de México, Mexico). Optical density (450 nm) was determined in an ELISA processor (Versamax microplate reader, Molecular Devisable, Sunnyvale, California, USA).

Plasmatic albendazole sulfoxide levels

Both patients showed hepatic and renal function in normal ranges. 4 mL-blood and CSF samples were collected at the seventh day of treatment, 8 hours after the last albendazole (ABZ) dose. Albendazole sulfoxide (ABZ-SO) was measured by HPLC and expressed in ng/mL.

During hospitalization, ABZ was administered at 30 mg/kg (ZENTEL, tablets 200 mg, GlaxoSmithKline) along with dexamethasone sodium phosphate at 0.3 mg/kg (Zymed) as substrate. The color reaction was allowed to proceed for 30 min at 37°C in the dark and was stopped by adding 100ml H2SO4 (Baker, Estado de México, Mexico). Optical density (450 nm) was determined in an ELISA processor (Versamax microplate reader, Molecular Devisable, Sunnyvale, California, USA).

Hormone profile

Shortly after blood collection, serum was separated and kept at 20°C until required. The concentration of the following hormones was measured by radioimmunoanalysis (RIA) using 125I tracer kits: testosterone (TESTO-CT2), luteinizing hormone (LH) (RIA-gnost hLH), prolactin (RIA-gnost PROL), and cortisol (CORT-CT2), all from CIS-bio international (Gif sur Yvette, France). Detection limits were: cortisol, 4.6nmol/L; testosterone, 0.1nmol/L; LH, 0.15mU/mL, and prolactin, 5μU/mL.

Results

CSF cytochemistry

A long-term clinical follow-up was conducted in both SABNC patients. As shown in Table 1, CSF from patient 1 showed little inflammatory traits until the fifth ABZ cycle. After the sixth cycle (20 months after treatment onset), the inflammatory reaction increased, with pleocytosis of 121 cells/mm³ associated with hypoglycorrachia. In patient 2, an inflammatory profile was observed since the first lumbar puncture with 773 cells/mm³, increasing to 3149 cells/mm³ after the first ABZ cycle, and with concomitant clinical manifestations of meningeal syndrome. Persistence of pleocytosis and hypoglycorrachia were observed in spite of intensive anti-inflammatory treatment.

Plasmatic levels of ABZ sulfoxide

ABZ sulfoxide levels were measured to evaluate whether the minimum therapeutic level of 1700 ng/mL proposed by Góngora-Rivera et al [10] as necessary to destroy cysticerci was reached in the central nervous system. As Table 1 shows, the concentration found in patient 1 after the fifth treatment cycle (3364.3 ng/mL), and the level in patient 2 after the first (2430 ng/mL) and second cycle (2421.8 ng/mL), were both above the minimum required.

CSF cytokine levels

Patient 1 showed high CSF-IFN levels before the first ABZ cycle and also high IL10 levels before the fifth ABZ cycle. Increased plasmatic TGF-β levels were found before each ABZ cycle. TNF-α level were irregular, but a 2-fold increase was found from the first to the fourth ABZ cycle.

Hormone profile

Plasmatic testosterone and cortisol levels were decreased, and LH levels were increased (Table 3). Patient 2 showed low IFN-γ levels and high IL-6 and IL-10 levels in CSF before treatment. Plasmatic testosterone, as well as prolactin and cortisol levels, were decreased, and LH levels were increased (Table 2).

The positive HP10 optical density in both patients confirmed the parasite viability throughout the clinical follow-up (Tables 1 & 2).

Renal and liver function tests were normal during all clinical follow-up.

Discussions and Conclusions

This study describes the clinical, immunological, and endocrine profiles of two SABNC patients with severe clinical manifestations, both of whom failed to respond to cysticidal treatment after several administration cycles with adequate albendazole sulfoxide levels. Persistent inflammatory characteristics were observed in CSF (hypoglycorrachia, hyperproteinorrachia, and pleocytosis). The secreted HP10 antigen levels found in both patients’ CSF and MRI results confirmed that cysticerci remained alive during all the evaluation period.

While we are aware of the reported differences between lumbar and ventricular CSF traits for inflammatory process during NC [11], in our study we analyzed lumbar CSF compartment and we found that the inflammatory profile (glucose, proteins and cell number) in both patients was accompanied with changes in cytokine levels that reinforce the possibility that an inflammatory process is occurring in the CNS.

Table 3: Immunoendocrinological profile of the two SABNC cases during ABZ cycles.

<table>
<thead>
<tr>
<th>C1</th>
<th>C2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABZ cycles</strong></td>
<td><strong>ABZ cycles</strong></td>
</tr>
<tr>
<td><strong>TGFβ</strong> (pg/mL)</td>
<td><strong>TGFβ</strong> (pg/mL)</td>
</tr>
<tr>
<td><strong>IFN-γ</strong> (pg/mL)</td>
<td><strong>IFN-γ</strong> (pg/mL)</td>
</tr>
<tr>
<td><strong>TNF-α</strong> (pg/mL)</td>
<td><strong>TNF-α</strong> (pg/mL)</td>
</tr>
<tr>
<td><strong>IL-6</strong> (pg/mL)</td>
<td><strong>IL-6</strong> (pg/mL)</td>
</tr>
<tr>
<td><strong>LH</strong> (mU/ml)**</td>
<td><strong>LH</strong> (mU/ml)**</td>
</tr>
<tr>
<td><strong>Testosterone (nmol/L)</strong></td>
<td><strong>Testosterone (nmol/L)</strong></td>
</tr>
<tr>
<td><strong>Prolactin (μU/mL)</strong></td>
<td><strong>Prolactin (μU/mL)</strong></td>
</tr>
<tr>
<td><strong>Cortisol (nmol/L)</strong></td>
<td><strong>Cortisol (nmol/L)</strong></td>
</tr>
</tbody>
</table>

C1 and C2 correspond to case 1 and 2, respectively. **Data retrieved in plasma. All other data are from CSF. ND: No data available. |
A decrease in prolactin levels was observed in patient B, while in both patients a sustained decrease in testosterone and cortisol levels was observed. Both NC patients exhibited an important reduction in testosterone levels with respect to those expected in the normal population and in our controls, a finding that points to possible endocrinological alterations in these patients, these finding have been previously reported findings in severe NC patients, like the two patients herein described [8]. Testosterone was also found decreased in naturally infected, cysticercotic boars in comparison with non-cysticercotic animals [12]. This has also been observed in mice chronically infected with Taenia crassiceps cysticerci. In these mice, testosterone is progressively reduced until the observed sex-hormone profile resembles that of female mice [13]. With regard to the relation between reduced testosterone levels and the infection, testosterone can affect directly the parasite growth. In vivo, the parasite could use the host steroid precursors for its own development, leading to a testosterone decrease during cysticercosis in humans, boars, and mice [8,14,15]. This testosterone consumption may result in its depletion, and it is a permissive factor for cysticercus development.

The mechanisms that mediate the neuroimmunoendocrine environment in the host merit some comments [6, 16-19]. Different modulating mechanisms have been reported in related parasites. Schistosome-specific phosphatidylserine (PS) activates TLR and affects dendritic cells; as a result, mature dendritic cells gained the ability to induce IL-10-producing regulatory T cells [20]. Also, excretory/secretory products of Echinococcus multilocularis larvae induce in vitro tolerogenic properties in dendritic cells [21]. These findings make conceivable that cysticercus-secreted molecules may promote a regulatory immune environment that may hamper the host response to the cysticidal treatment. Recently, it has been reported that viable cysticerci induce regulatory T cells [22], using dendritic cells as intermediary [23]. Therefore, it is possible that parasites could favor a regulatory environment to survive in an immunocompetent host, in spite of treatment.

With regard to the complex interactions between hormones and the immune system, it has been extensively reported that the incidence and severity of natural parasitic infections show a sexual dimorphism that involves a distinct exposure in males and females to various parasite infective stages; likewise, differential effects of sex steroids on immune cells and direct effects of these steroids on parasites, among other effects, have also been reported. Typically, the prevalence and intensity of a large number of parasitic diseases are higher in males than in females. However, in several parasitic infections males are more resistant than females [24].

Taken together, these data pointed out to a possible deep impact of severe cysticercal infection on the immune-inflammatory and endocrine status of NC patients.

Acknowledgement

Authors thank Juan Francisco Rodriguez for proofreading the English version of this manuscript. This study was supported by CONACYT (CB-2008-01 100708, CB-2011-01 167278) and by DGAPA IN213911.

References

17. Morales-Montor J, Hall CA. The host-parasite neuroimmunoendocrine
network in schistosomiasis: consequences to the host and the parasite. See comment in PubMed Commons below Parasite Immunol. 2007; 29: 599-608.


